Subgroup outcomes from RAISE: A randomized, Phase 3 trial of zilucoplan in generalized myasthenia gravis

被引：0
|
作者：
Weiss, Michael D. [1 ]
Bresch, Saskia [2 ]
Freimer, Miriam [3 ]
Hewamadduma, Channa [4 ]
Juntas-Morales, Raul [5 ]
Leite, M. Isabel [6 ]
Maniaol, Angelina [7 ]
Masuda, Masayuki [8 ]
Sivakumar, Kumaraswamy [9 ]
Zajda, Malgorzata [10 ]
Boroojerdi, Babak [11 ]
Duda, Petra W. [12 ]
De La Borderie, Guillemette [13 ]
Howard, James F., Jr. [14 ]
机构：
[1] Univ Washington, Med Ctr, Dept Neurol, Seattle, WA USA
[2] Ctr Hosp Univ Nice, Nice, France
[3] Ohio State Univ, Columbus, OH USA
[4] Univ Sheffield, Dept Neurosci, Sheffield, S Yorkshire, England
[5] Vall dHebron Univ Hosp, Barcelona, Spain
[6] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England
[7] Oslo Univ Hosp, Dept Neurol, Oslo, Norway
[8] Tokyo Med Univ, Dept Neurol, Tokyo, Japan
[9] Univ Arizona, Sch Med, Neuromuscular Clin & Res Ctr, Tucson, AZ USA
[10] Med Univ Warsaw, Warsaw, Poland
[11] UCB Pharma, Monheim, Germany
[12] UCB Pharma, Cambridge, MA USA
[13] UCB Pharma, Brussels, Belgium
[14] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000202904
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1-5.006
引用
收藏
页数：5
相关论文
共 50 条
  • [41] NON-STEROIDAL IMMUNOSUPPRESSANT THERAPY CHANGES DURING TREATMENT WITH ZILUCOPLAN IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: 120-WEEK FOLLOW-UP OF RAISE-XT
    Vu, Tuan
    Freimer, Miriam
    Genge, Angela
    Hewamadduma, Channa
    Leite, M. Isabel
    Utsugisawa, Kimiaki
    Boroojerdi, Babak
    Grimson, Fiona
    Savic, Natasa
    Howard, James F., Jr.
    MUSCLE & NERVE, 2024, 70 (03) : 689 - 690
  • [42] Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis
    Wolfe, GI
    Barohn, RJ
    Foster, BM
    Jackson, CE
    Kissel, JT
    Day, JW
    Thornton, CA
    Nations, SP
    Bryan, WW
    Amato, AA
    Freimer, ML
    Parry, GJ
    Mendell, JR
    MUSCLE & NERVE, 2002, 26 (04) : 549 - 552
  • [43] Long-term safety, efficacy & self-injection satisfaction with zilucoplan in myasthenia gravis: RAISE-XT interim analysis
    Genge, Angela
    Leite, M. Isabel
    Bresch, Saskia
    Freimer, Miriam
    Hewamadduma, Channa
    Hussain, Yessar
    Maniaol, Angelina
    Mantegazza, Renato
    Smilowski, Marek
    Utsugisawa, Kimiaki
    Vu, Tuan
    Duda, Petra W.
    Boroojerdi, Babak
    Vanderkelen, Mark
    De la Borderie, Guillemette
    Bloemers, Jos
    Howard, James F., Jr.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [44] EXAMINATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF EFGARTIGIMOD IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY SERONEGATIVE PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: SUBGROUP ANALYSIS OF PHASE 3
    Howard, James
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan L.
    Murai, Hiroyuki
    Pasnoor, Mamatha
    Sacca, Francesco
    Meisel, Andreas
    Guglietta, Antonio
    T'joen, Caroline
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    MUSCLE & NERVE, 2021, 64 : S5 - S5
  • [45] Long-term safety, efficacy & self-injection satisfaction with zilucoplan in myasthenia gravis: RAISE-XT interim analysis
    Leite, M.
    Bresch, S.
    Freimer, M.
    Genge, A.
    Hewamadduma, C.
    Hussain, Y.
    Maniaol, A.
    Mantegazza, R.
    Smilowski, M.
    Utsugisawa, K.
    Vu, T.
    Duda, P.
    Boroojerdi, B.
    Vanderkelen, M.
    De la Borderie, G.
    Bloemers, J.
    Howard, J., Jr.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 462 - 462
  • [46] Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis
    Hewett, Karen
    Sanders, Donald B.
    Grove, Richard A.
    Broderick, Christine L.
    Rudo, Todd J.
    Bassiri, Ashlyn
    Zvartau-Hind, Marina
    Bril, Vera
    NEUROLOGY, 2018, 90 (16) : E1425 - E1434
  • [47] Thymectomy improves outcomes in myasthenia gravis, trial shows
    Mayor, Susan
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 354
  • [48] Long-term safety, efficacy & self-injection satisfaction with zilucoplan in myasthenia gravis: RAISE-XT interim analysis
    Farmakidis, C.
    Leite, M.
    Bresch, S.
    Freimer, M.
    Genge, A.
    Hewamadduma, C.
    Hussain, Y.
    Maniaol, A.
    Mantegazza, R.
    Smilowski, M.
    Utsugisawa, K.
    Vu, T.
    Duda, P.
    Boroojerdi, B.
    Vanderkelen, M.
    de la Borderie, G.
    Bloemers, J.
    Howard, J., Jr.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S178 - S178
  • [49] Zilucoplan, a subcutaneously self-administered peptide inhibitor of complement component 5 (C5), for the treatment of generalized myasthenia gravis: results of a Phase 2 randomized, double-blind, placebo-controlled trial
    Howard, J. F.
    Nowak, R. J.
    Wolfe, G. I.
    Benatar, M. G.
    Macdougall, J.
    Duda, P. W.
    Far, R. Farzaneh
    Kaminski, H. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 41 - 41
  • [50] THE PHASE 3 PREVAIL STUDY ASSESSING THE EFFICACY AND SAFETY OF SUBCUTANEOUS GEFURULIMAB IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS: TRIAL IN PROGRESS
    Howard, James F., Jr.
    Gwathmey, Kelly G.
    Zhao, Chongbo
    Rakhade, Sanjay
    Scholz, Joachim
    Pelaez-Rivas, Alexandra
    Racine, Annie M.
    McEneny, Alanna
    Shang, Shulian
    Vu, Tuan
    MUSCLE & NERVE, 2024, 70 (03) : 709 - 709
12345